Lorus Therapeutics Announces Positive Anticancer Data for IL-17E at AACR Tumor Immunology Conference
Related posts:
- Lorus Therapeutics Presents Positive Data for Lead Anticancer Drug LOR-253
- Lorus Therapeutics Announces Issuance of Patent for Anticancer Drug LOR-253 in Canada
- Lorus Therapeutics Announces Allowance of United States Patent for Anticancer Drug LOR-253
- Lorus Therapeutics Announces Clinical Study Progress With Its Anticancer Drug LOR-253 and Expansion to a Second Major Site
- Lorus Therapeutics Announces Positive Results from Its Small Molecule Antimicrobial Program
VentriPoint to Exhibit at EUROECHO 2012 in Athens
…continued
Drugs Healthcare …continued
Healthcare
Related posts:
- VentriPoint VMS(TM) Heart Analysis System Installed at University Children’s Hospital in Zurich, Switzerland
- VentriPoint Exhibits at 46th Annual Meeting of the Association of European Paediatric Cardiologists
- VentriPoint to Be Featured on "The Next Biggest Winner" on iChannel
- VentriPoint Signs Joint Development Agreement With Brand Name Global Ultrasound Manufacturer
- VentriPoint Launches Updated Version of VMS(TM) Heart Analysis System in Europe and Canada
Akela Pharma, Inc. announces voluntary delisting from the Toronto Stock Exchange
Related posts:
- SemBioSys announces voluntary delisting from Toronto Stock Exchange and pursuit of strategic alternatives
- SemBioSys provides update regarding voluntary delisting from Toronto Stock Exchange and the current state of the company
- Spur Ventures Inc.: Listing on TSX Venture Exchange and Voluntary Delisting From Toronto Stock Exchange
- Gold Reserve Inc. Announces Notification of Delisting from the Toronto Stock Exchange
- Gold Reserve Inc. announces notification of delisting from the Toronto Stock Exchange
IIROC Trade Resumption – Lorus Therapeutics Inc.
Related posts:
- IIROC Trade Halt – Lorus Therapeutics Inc.
- IIROC Trade Resumption – Pantheon Ventures Ltd
- IIROC Trade Resumption – Danier Leather Inc.
- IIROC Trade Resumption – Southern Arc Minerals Inc.
- IIROC Trade Resumption – Kingsland Energy Corp.
IIROC Trade Halt – Lorus Therapeutics Inc.
…continued
…continued
Healthcare Drugs
Related posts:
- IIROC Trade Halt – Connacher Oil and Gas Limited
- IIROC Trade Halt – Landdrill International Inc.
- IIROC Trade Halt – Pantheon Ventures Ltd.
- IIROC Trade Halt – Andor Mining Inc.
- IIROC Trade Halt – Danier Leather Inc.
Stem Cell Therapeutics Announces Share Consolidation Proposal
Related posts:
- Stem Cell Therapeutics Announces Share Consolidation Proposal
- Stem Cell Therapeutics Announces Reorganization and Management Changes
- Stem Cell Therapeutics Announces Additions to Advisory Board
- Stem Cell Therapeutics Corp. Provides Corporate Update
- Stem Cell Therapeutics Reports 2011 Year End Results
Stem Cell Therapeutics Announces Share Consolidation Proposal
Related posts:
- Stem Cell Therapeutics Announces Reorganization and Management Changes
- Stem Cell Therapeutics Announces Additions to Advisory Board
- Stem Cell Therapeutics Corp. Provides Corporate Update
- Stem Cell Therapeutics Reports 2011 Year End Results
- Portal Announces Proposed Share Consolidation, Amendment to Authorized Share Capital and Name Change
Update on Steenkampskraal Rare Earth Chloride Plant, LCM Alloy Production, GWTI Project, CEO Search and PEA
…continued
Healthcare Drugs …continued
mining
Related posts:
- Great Western Minerals Group Files NI 43-101 Resource Estimate and Technical Report on Steenkampskraal Rare Earth Property
- Montero Announces the Presence of Strontium in the Mineralized Rare Earth Bearing Dikes at the Wigu Hill Rare Earth Project, Tanzania
- Montero Produces First Samples of Rare Earth Saleable Products From the Wigu Hill Rare Earth Project in Tanzania
- Eased Policies on Exports and New Production Sources Reasons for Rare Earth Prices Decline in 2012
- Avalon Reports on Successful Pilot Plant Campaigns for the Nechalacho Rare Earth Element Project, Thor Lake, NWT
Paladin Labs Announces the Canadian Launch of Oralair(TM)
Related posts:
- Paladin Labs Announces the Canadian Launch of Oralair(TM)
- Paladin Labs Announces the Canadian Launch of DigiFab(TM) Digoxin Immune Fab (Ovine)
- Paladin Labs and Nuvo Research Sign Canadian License Agreement for Synera and a Loan Agreement
- Nuvo Research and Paladin Labs Sign Canadian License Agreement for Synera and a Loan Agreement
- Nuvo Research and Paladin Labs Sign Canadian License Agreement for Synera and a Loan Agreement
Paladin Labs Announces the Canadian Launch of Oralair(TM)
…continued
Drugs Healthcare …continued
Healthcare Drugs
Related posts:
- Paladin Labs Announces the Canadian Launch of Oralair(TM)
- Paladin Labs Announces the Canadian Launch of DigiFab(TM) Digoxin Immune Fab (Ovine)
- Paladin Labs and Nuvo Research Sign Canadian License Agreement for Synera and a Loan Agreement
- Nuvo Research and Paladin Labs Sign Canadian License Agreement for Synera and a Loan Agreement
- Nuvo Research and Paladin Labs Sign Canadian License Agreement for Synera and a Loan Agreement
Pure Industrial Real Estate Trust Announces $169.2 Million of Property Acquisitions and $50 Million Equity Financing
…continued
Drugs Healthcare …continued
Healthcare Drugs …continued
Financial
Related posts:
- Pure Industrial Real Estate Trust announces $46.9 million of property acquisitions and $26.5 million equity financing
- Pure Industrial Real Estate Trust Announces Agreement to Acquire Fully Leased Industrial Property for $8.25 Million and Redemption of Restricted Units
- Pure Industrial Real Estate Trust Announces Agreement to Acquire Fully Leased Industrial Property for $8.25 Million and Redemption of Restricted Units
- Pure Industrial Real Estate Trust Announces Agreement to Acquire Two Fully Leased Industrial Properties for $19.5 Million and Closing of Previously Announced $7.28 Million Transaction
- Pure Industrial Real Estate Trust Announces Agreement to Acquire Two Fully Leased Industrial Properties for $19.5 Million and Closing of Previously Announced $7.28 Million Transaction
Tekmira Provides Corporate Update and Announces Third Quarter 2012 Results
Related posts:
- Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
- Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter 2012 Results
- Tekmira Conference Call and Webcast Advisory: Corporate Update and Second Quarter 2012 Results
- Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter 2012 Results
- Tekmira Provides Corporate Update and Announces 2011 Results
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter 2012 Results
Related posts:
- Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter 2012 Results
- Tekmira Conference Call and Webcast Advisory: Corporate Update and Second Quarter 2012 Results
- Tekmira Conference Call and Webcast Advisory: Corporate Update and 2011 Audited Results
- Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
- Phone Conference and Webcast: Corporate Update on SENSIO-First Quarter 2011-2012 Results
Tekmira and Alnylam Restructure Relationship and Settle All Litigation
Related posts:
- TNR Gold Offers to Settle Los Azules Litigation With Minera Andes for US$125 Million
- Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
- Tekmira Provides Corporate Update and Announces 2011 Results
- Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
- Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
Reminder – Media advisory – Incident in Sherbrooke – Neptune Technologies & Bioressources reiterates its most sincere condolences to the families of the three victims and will provide an update on the situation
…continued
Drugs careers astaxanthin
Related posts:
- Media advisory – Incident in Sherbrooke – Neptune Technologies & Bioressources reiterates its most sincere condolences to the families of the three victims and will provide an update on the situation
- MEDIA ADVISORY: Dr. Sherry Cooper, BMO Chief Economist, to Provide Outlook for Economy and Labour Market in Vancouver
- REPEAT-MEDIA ADVISORY: Dr. Sherry Cooper, BMO Chief Economist, to Provide Outlook for Economy and Labour Market in Vancouver
- Neptune Technologies & Bioressources Common Shares Graduate to the TSX
- /R E P E A T — Media Advisory – Astral Media Inc. – Fiscal 2011 Annual and Special Meeting of Shareholders/
Oncolytics Biotech Inc. Collaborators Present Positive REOLYSIN Trial Results and Research at EORTC-NCI-AACR Symposium
…continued
Energy …continued
Healthcare Drugs Drugs
Related posts:
- MethylGene to Present at the American Association for Cancer Research (AACR) Annual Meeting
- Media Advisory – Oncolytics Biotech( Inc. to Present at Cowen and Company 32nd Annual Health Care Conference
- Media Advisory – Oncolytics Biotech( Inc. to Present at Cowen and Company 32nd Annual Health Care Conference
- Oncolytics Announces Independent Data Monitoring Committee Recommends Continued Enrollment in Phase III Study of REOLYSIN in Head and Neck Cancers Following Review of Safety Data
- Oncolytics Announces Independent Data Monitoring Committee Recommends Continued Enrollment in Phase III Study of REOLYSIN in Head and Neck Cancers Following Review of Safety Data
YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
…continued
biotechnology Healthcare Drugs
Related posts:
- YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
- YM BioSciences Reports Fiscal 2012 Operational and Financial Results
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
…continued
biotechnology Healthcare Drugs …continued
pharmaceutical pharma biotech
Related posts:
- YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
- YM BioSciences Reports Fiscal 2012 Operational and Financial Results
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2012
- YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012
Microbix Announces Extension and Re-Pricing of Share Purchase Warrants
Related posts:
- Grandview Gold Inc. Announces the Appointment of Mr. Carmello Marrelli as CFO and the Extension of the Expiry Date of Certain Outstanding Common Share Purchase Warrants
- Prophecy Coal Announces Extension and Re-Pricing of Warrants
- Prophecy Coal Announces Extension and Re-Pricing of Warrants
- Mainstream Minerals Corporation announces its intention to extend the term of the Series N common share purchase warrants by 12 months
- Mainstream Minerals Corporation announces its intention to extend the term of the Series N common share purchase warrants by 12 months
ProMetic Presenting Positive New Anti-Fibrotic Data at the American Society of Nephrology Annual Meeting in San Diego
Related posts:
- ProMetic Presenting Positive New Anti-Fibrotic Data at the American Society of Nephrology Annual Meeting in San Diego
- MethylGene to Present MGCD265 Data at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
- MethylGene Presents MGCD265 Data at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
- Skin Cancer Imaging with MoleMate Featured At Annual Shareholder’s Meeting and Upcoming American Academy of Dermatology Meeting in San Diego
- MethylGene Presents Preclinical Data for MGCD265 at the American Association for Cancer Research (AACR) Annual Meeting
ProMetic Presenting Positive New Anti-Fibrotic Data at the American Society of Nephrology Annual Meeting in San Diego
…continued
Healthcare Drugs …continued
Drugs Healthcare
Related posts:
- ProMetic Presenting Positive New Anti-Fibrotic Data at the American Society of Nephrology Annual Meeting in San Diego
- MethylGene to Present MGCD265 Data at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
- MethylGene Presents MGCD265 Data at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
- Skin Cancer Imaging with MoleMate Featured At Annual Shareholder’s Meeting and Upcoming American Academy of Dermatology Meeting in San Diego
- MethylGene Presents Preclinical Data for MGCD265 at the American Association for Cancer Research (AACR) Annual Meeting
Theratechnologies Inc.: Revenue Growth and Expenditure Control at the Core of Revised Business Plan
Related posts:
- Theratechnologies Inc.: Revenue Growth and Expenditure Control at the Core of Revised Business Plan
- Changfeng Reports Continued Strong Revenue and EBITDA Growth in Fiscal Year 2011 and Provides Business Updates
- Changfeng Reports Continued Strong Revenue and EBITDA Growth in Fiscal Year 2011 and Provides Business Updates
- Changfeng Corrects Two Typographical Errors in the Press Release Titled "Changfeng Reports Continued Strong Revenue and EBITDA Growth in Fiscal Year 2011 and Provides Business Updates"
- Crescent Point Announces Strategic Viking Consolidation Acquisition, Minor Disposition of Non-Core Alberta Assets and Upwardly Revised 2012 Capital Expenditures and Guidance
Theratechnologies Inc.: Revenue Growth and Expenditure Control at the Core of Revised Business Plan
…continued
Drugs Healthcare …continued
Drugs Healthcare
Related posts:
- Changfeng Reports Continued Strong Revenue and EBITDA Growth in Fiscal Year 2011 and Provides Business Updates
- Changfeng Reports Continued Strong Revenue and EBITDA Growth in Fiscal Year 2011 and Provides Business Updates
- Changfeng Corrects Two Typographical Errors in the Press Release Titled "Changfeng Reports Continued Strong Revenue and EBITDA Growth in Fiscal Year 2011 and Provides Business Updates"
- Crescent Point Announces Strategic Viking Consolidation Acquisition, Minor Disposition of Non-Core Alberta Assets and Upwardly Revised 2012 Capital Expenditures and Guidance
- Crescent Point Announces Strategic Viking Consolidation Acquisition, Minor Disposition of Non-Core Alberta Assets and Upwardly Revised 2012 Capital Expenditures and Guidance
iCo Therapeutics Engages HT Capital for Investor Communication Services
Related posts:
- GTA Resources and Mining Inc. Engages First Canadian Capital Corp. for Investor Relations Services
- Darford International Inc. Engages Caliber Capital Partners Inc. for Investor Relations Services and Grants Stock Options
- Canadian Orebodies Engages First Canadian Capital Corp for Investor Relations and Grant of Options
- GTA Resources and Mining Inc. Grants Options to First Canadian Capital Corp. for Investor Relations Services
- Orex Engages Senior Communications and Investor Relations Consultant
Theratechnologies Announces Departure of President and Chief Executive Officer
Related posts:
- Theratechnologies Announces Departure of President and Chief Executive Officer
- SNC-Lavalin announces departure of Chief Executive Officer, appointment of Interim Chief Executive Officer and fourth quarter and year-end results for 2011
- Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
- PetroBakken Announces Departure of Senior Vice President and Chief Operating Officer
- Cominar announces Sylvain Cossette to join executive management team as Executive Vice-President and Chief Operating Officer
